{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:46:08Z","timestamp":1790523968251,"version":"4.1.0"},"reference-count":49,"publisher":"American Association for Cancer Research (AACR)","issue":"7","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To understand the mechanism of cellular resistance to the nucleoside analogue cytarabine (1-\u03b2-d-arabinofuranosylcytosine, AraC), two resistant derivatives of the human leukemic line CCRF-CEM were obtained by stepwise selection in different concentrations of AraC. CEM\/4\u00d7AraC cells showed low AraC resistance, whereas CEM\/20\u00d7AraC cells showed high resistance. Both cell lines showed similar patterns of cross-resistance to multiple cytotoxic nucleoside analogues, with the exception that CEM\/20\u00d7AraC cells remained sensitive to 5-fluorouridine and 2-deoxy-5-fluorouridine. Both cell lines were sensitive to 5-fluorouracil and to a variety of natural product drugs. Although both CEM\/4\u00d7AraC and CEM\/20\u00d7AraC cells displayed reduced intracellular accumulation of [3H]AraC, only CEM\/4\u00d7AraC cells showed reduced uptake of [3H]uridine, which was used to assess nucleoside transport activities. Genes encoding proteins known to be involved in nucleoside transport, efflux, and metabolism were analyzed for the presence of mutations in the two cell lines. In CEM\/4\u00d7AraC cells, independent mutations were identified at each allele of human equilibrative nucleoside transporter 1 (hENT1; SLC29A1), one corresponding to a single-nucleotide change in exon 4, the other being a complex intronic mutation disrupting splicing of exon 13. In contrast to CEM\/20\u00d7AraC cells, CEM\/4\u00d7AraC cells did not bind the hENT1\/SLC29A1 ligand nitrobenzylmercaptopurine ribonucleoside and lacked detectable hENT1\/SLC29A1 protein. In CEM\/20\u00d7AraC cells, independent intronic mutations impairing splicing of exons 2 and 3 were found at each allele of the deoxycytidine kinase gene. These studies point to at least two distinct mechanisms of AraC resistance in leukemic cells. [Cancer Res 2008;68(7):2349\u201357]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-5528","type":"journal-article","created":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T15:44:16Z","timestamp":1207064656000},"page":"2349-2357","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Two Distinct Molecular Mechanisms Underlying Cytarabine Resistance in Human Leukemic Cells"],"prefix":"10.1158","volume":"68","author":[{"given":"Jie","family":"Cai","sequence":"first","affiliation":[{"name":"1Department of Biochemistry, McGill University, Montreal, Quebec, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya L.","family":"Damaraju","sequence":"additional","affiliation":[{"name":"2Department of Oncology, University of Alberta and Cross Cancer Institute, Edmonton, Alberta, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Normand","family":"Groulx","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry, McGill University, Montreal, Quebec, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delores","family":"Mowles","sequence":"additional","affiliation":[{"name":"2Department of Oncology, University of Alberta and Cross Cancer Institute, Edmonton, Alberta, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunshan","family":"Peng","sequence":"additional","affiliation":[{"name":"3Department of Chemistry and Biochemistry, Brigham Young University, Provo, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris J.","family":"Robins","sequence":"additional","affiliation":[{"name":"3Department of Chemistry and Biochemistry, Brigham Young University, Provo, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol E.","family":"Cass","sequence":"additional","affiliation":[{"name":"2Department of Oncology, University of Alberta and Cross Cancer Institute, Edmonton, Alberta, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gros","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry, McGill University, Montreal, Quebec, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,4,1]]},"reference":[{"key":"2022061700300162800_B1","doi-asserted-by":"crossref","unstructured":"Thomas X, Dombret H. Timed-sequential chemotherapy as induction and\/or consolidation regimen for younger adults with acute myelogenous leukemia. Hematology\u20082007; 12: 15\u201328.","DOI":"10.1080\/10245330600938240"},{"key":"2022061700300162800_B2","doi-asserted-by":"crossref","unstructured":"Tsurumi H, Kanemura N, Hara T, et al. Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy of continuous drip infusion with low dose cytarabine and etoposide. J Cancer Res Clin Oncol\u20082007; 133: 547\u201353.","DOI":"10.1007\/s00432-007-0203-3"},{"key":"2022061700300162800_B3","doi-asserted-by":"crossref","unstructured":"Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of three randomized trials. Cancer\u20082006; 107: 116\u201324.","DOI":"10.1002\/cncr.21543"},{"key":"2022061700300162800_B4","doi-asserted-by":"crossref","unstructured":"Tedeschi A, Montillo M, Strocchi E, et al. High-dose idarubicin in combination with AraC in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Cancer Chemother Pharmacol\u20082007; 59: 771\u20139.","DOI":"10.1007\/s00280-006-0332-4"},{"key":"2022061700300162800_B5","doi-asserted-by":"crossref","unstructured":"Candoni A, Michelutti A, Simeone E, Damiani D, Baccarani M, Fanin R. Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins. Eur J Haematol\u20082006; 77: 293\u20139.","DOI":"10.1111\/j.1600-0609.2006.00708.x"},{"key":"2022061700300162800_B6","doi-asserted-by":"crossref","unstructured":"Giebel S, Krawczyk-Kulis M, Adamczyk-Cioch M, et al. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG). Ann Hematol\u20082006; 85: 717\u201322.","DOI":"10.1007\/s00277-006-0121-5"},{"key":"2022061700300162800_B7","doi-asserted-by":"crossref","unstructured":"Oki Y, Ogura M, Kato H, et al. Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Sci. Epub 2007 Nov 7.","DOI":"10.1111\/j.1349-7006.2007.00662.x"},{"key":"2022061700300162800_B8","doi-asserted-by":"crossref","unstructured":"Jo JC, Kang BW, Jang G, et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol. Epub 2007 Aug 21.","DOI":"10.1007\/s00277-007-0360-0"},{"key":"2022061700300162800_B9","doi-asserted-by":"crossref","unstructured":"Mey UJ, Orlopp KS, Flieger D, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest\u20082006; 24: 593\u2013600.","DOI":"10.1080\/07357900600814490"},{"key":"2022061700300162800_B10","doi-asserted-by":"crossref","unstructured":"Lassaletta A, Perez-Olleros P, Scaglione C, et al. Successful treatment of intracranial ependymoma with leptomeningeal spread with systemic chemotherapy and intrathecal liposomal cytarabine in a two-year-old child. J Neurooncol\u20082007; 83: 303\u20136.","DOI":"10.1007\/s11060-006-9327-6"},{"key":"2022061700300162800_B11","doi-asserted-by":"crossref","unstructured":"Ravindranath Y, Chang M, Steuber CP, et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia\u20082005; 19: 2101\u201316.","DOI":"10.1038\/sj.leu.2403927"},{"key":"2022061700300162800_B12","doi-asserted-by":"crossref","unstructured":"Liang DC, Chan TT, Lin KH, et al. Improved treatment results for childhood acute myeloid leukemia in Taiwan. Leukemia\u20082006; 20: 136\u201341.","DOI":"10.1038\/sj.leu.2403979"},{"key":"2022061700300162800_B13","doi-asserted-by":"crossref","unstructured":"Damaraju VL, Damaraju S, Young JD, et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene\u20082003; 22: 7524\u201336.","DOI":"10.1038\/sj.onc.1206952"},{"key":"2022061700300162800_B14","doi-asserted-by":"crossref","unstructured":"Hubeek I, Stam RW, Peters GJ, et al. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer\u20082005; 93: 1388\u201394.","DOI":"10.1038\/sj.bjc.6602881"},{"key":"2022061700300162800_B15","doi-asserted-by":"crossref","unstructured":"Sarkar M, Han T, Damaraju V, Carpenter P, Cass CE, Agarwal RP. Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells. Biochem Pharmacol\u20082005; 70: 426\u201332.","DOI":"10.1016\/j.bcp.2005.05.014"},{"key":"2022061700300162800_B16","doi-asserted-by":"crossref","unstructured":"Stam RW, den Boer ML, Meijerink JP, et al. Differential mRNA expression of AraC-metabolizing enzymes explains AraC sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood\u20082003; 101: 1270\u20136.","DOI":"10.1182\/blood-2002-05-1600"},{"key":"2022061700300162800_B17","doi-asserted-by":"crossref","unstructured":"Zhang J VF, King KM, Baldwin SA, Young JD, Cass CE. The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev\u20082007; 26: 85\u2013110.","DOI":"10.1007\/s10555-007-9044-4"},{"key":"2022061700300162800_B18","doi-asserted-by":"crossref","unstructured":"Kanno S, Hiura T, Ohtake T, et al. Characterization of resistance to cytosine arabinoside (AraC) in NALM-6 human B leukemia cells. Clin Chim Acta\u20082007; 377: 144\u20139.","DOI":"10.1016\/j.cca.2006.09.014"},{"key":"2022061700300162800_B19","doi-asserted-by":"crossref","unstructured":"Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci\u20082004; 95: 753\u20137.","DOI":"10.1111\/j.1349-7006.2004.tb03257.x"},{"key":"2022061700300162800_B20","doi-asserted-by":"crossref","unstructured":"Osato DH, Huang CC, Kawamoto M, et al. Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. Pharmacogenetics\u20082003; 13: 297\u2013301.","DOI":"10.1097\/00008571-200305000-00010"},{"key":"2022061700300162800_B21","doi-asserted-by":"crossref","unstructured":"Kim SR, Saito Y, Maekawa K, et al. Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1). Drug Metab Pharmacokinet\u20082006; 21: 248\u201356.","DOI":"10.2133\/dmpk.21.248"},{"key":"2022061700300162800_B22","doi-asserted-by":"crossref","unstructured":"Myers SN, Goyal RK, Roy JD, Fairfull LD, Wilson JW, Ferrell RE. Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1. Pharmacogenet Genom\u20082006; 16: 315\u201320.","DOI":"10.1097\/01.fpc.0000189804.41962.15"},{"key":"2022061700300162800_B23","doi-asserted-by":"crossref","unstructured":"Momparler RL, Laliberte J, Eliopoulos N, Beausejour C, Cournoyer D. Transfection of murine fibroblast cells with human cytidine deaminase cDNA confers resistance to cytosine arabinoside. Anticancer Drugs\u20081996; 7: 266\u201374.","DOI":"10.1097\/00001813-199605000-00005"},{"key":"2022061700300162800_B24","unstructured":"Schroder JK, Kirch C, Flasshove M, et al. Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. Leukemia\u20081996; 10: 1919\u201324."},{"key":"2022061700300162800_B25","unstructured":"Neff T, Blau CA. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol\u20081996; 24: 1340\u20136."},{"key":"2022061700300162800_B26","doi-asserted-by":"crossref","unstructured":"Galmarini CM, Graham K, Thomas X, et al. Expression of high Km 5\u2032-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood\u20082001; 98: 1922\u20136.","DOI":"10.1182\/blood.V98.6.1922"},{"key":"2022061700300162800_B27","doi-asserted-by":"crossref","unstructured":"Galmarini CM, Thomas X, Calvo F, et al. Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res\u20082002; 26: 621\u20139.","DOI":"10.1016\/S0145-2126(01)00184-9"},{"key":"2022061700300162800_B28","doi-asserted-by":"crossref","unstructured":"Jordheim LP, Guittet O, Lepoivre M, Galmarini CM, Dumontet C. Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Mol Cancer Ther\u20082005; 4: 1268\u201376.","DOI":"10.1158\/1535-7163.MCT-05-0121"},{"key":"2022061700300162800_B29","doi-asserted-by":"crossref","unstructured":"Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res\u20082004; 64: 3761\u20136.","DOI":"10.1158\/0008-5472.CAN-03-3363"},{"key":"2022061700300162800_B30","doi-asserted-by":"crossref","unstructured":"Mansson E, Flordal E, Liliemark J, et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol\u20082003; 65: 237\u201347.","DOI":"10.1016\/S0006-2952(02)01484-3"},{"key":"2022061700300162800_B31","doi-asserted-by":"crossref","unstructured":"Rooseboom M, Commandeur JN, Vermeulen NP. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev\u20082004; 56: 53\u2013102.","DOI":"10.1124\/pr.56.1.3"},{"key":"2022061700300162800_B32","doi-asserted-by":"crossref","unstructured":"Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenom J\u20082005; 5: 226\u201343.","DOI":"10.1038\/sj.tpj.6500320"},{"key":"2022061700300162800_B33","doi-asserted-by":"crossref","unstructured":"King AE AM, Cass CE, Young JD, Baldwin SA. Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci\u20082006; 27: 416\u201325.","DOI":"10.1016\/j.tips.2006.06.004"},{"key":"2022061700300162800_B34","doi-asserted-by":"crossref","unstructured":"Jennings LL, Hao C, Cabrita MA, et al. Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system. Neuropharmacology\u20082001; 40: 722\u201331.","DOI":"10.1016\/S0028-3908(00)00207-0"},{"key":"2022061700300162800_B35","doi-asserted-by":"crossref","unstructured":"Visser F SL, Damaraju V, Tackaberry T, et al. Residues 334 and 338 in transmembrane segment 8 of human equilibrative nucleoside transporter 1 are important determinants of inhibitor sensitivity, protein folding, and catalytic turnover. J Biol Chem\u20082007; 282: 14148\u201357.","DOI":"10.1074\/jbc.M701735200"},{"key":"2022061700300162800_B36","doi-asserted-by":"crossref","unstructured":"Jamieson GP BA, Snook MB, Sawyer WH, Buolamwini JK, Paterson AR, Wiley JS. Flow cytometric quantitation of nucleoside transporter sites on human leukemic cells. Cytometry\u20081993; 14: 32\u20138.","DOI":"10.1002\/cyto.990140107"},{"key":"2022061700300162800_B37","doi-asserted-by":"crossref","unstructured":"Crawford CR, Ng CY, Ullman B, Belt JA. Identification and reconstitution of the nucleoside transporter of CEM human leukemia cells. Biochim Biophys Acta\u20081990; 1024: 289\u201397.","DOI":"10.1016\/0005-2736(90)90357-T"},{"key":"2022061700300162800_B38","doi-asserted-by":"crossref","unstructured":"Takagaki K, Katsuma S, Kaminishi Y, et al. Gene-expression profiling reveals down-regulation of equilibrative nucleoside transporter 1 (ENT1) in AraC-resistant CCRF-CEM-derived cells. J Biochem (Tokyo)\u20082004; 136: 733\u201340.","DOI":"10.1093\/jb\/mvh180"},{"key":"2022061700300162800_B39","unstructured":"Mackey JR, Mani RS, Selner M, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res\u20081998; 58: 4349\u201357."},{"key":"2022061700300162800_B40","unstructured":"Marce S, Molina-Arcas M, Villamor N, et al. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica\u20082006; 91: 895\u2013902."},{"key":"2022061700300162800_B41","unstructured":"Galmarini CM. Correlation of hENT1 expression and function with gemcitabine cytotoxicity in mantle cell lymphoma lines and clinical samples. Haematologica\u20082006; 91: 866B."},{"key":"2022061700300162800_B42","doi-asserted-by":"crossref","unstructured":"Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene\u20082003; 22: 7468\u201385.","DOI":"10.1038\/sj.onc.1206948"},{"key":"2022061700300162800_B43","doi-asserted-by":"crossref","unstructured":"Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov\u20082006; 5: 219\u201334.","DOI":"10.1038\/nrd1984"},{"key":"2022061700300162800_B44","doi-asserted-by":"crossref","unstructured":"Stegmann AP, Honders MW, Hagemeijer A, Hoebee B, Willemze R, Landegent JE. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2\u2032-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene. Ann Hematol\u20081995; 71: 41\u20137.","DOI":"10.1007\/BF01696231"},{"key":"2022061700300162800_B45","unstructured":"Stegmann AP, Honders MW, Willemze R, Landegent JE. De novo induced mutations in the deoxycytidine kinase (dck) gene in rat leukemic clonal cell lines confer resistance to cytarabine (AraC) and 5-aza-2\u2032-deoxycytidine (DAC). Leukemia\u20081995; 9: 1032\u20138."},{"key":"2022061700300162800_B46","doi-asserted-by":"crossref","unstructured":"Stegmann AP, Honders WH, Willemze R, Ruiz van Haperen VW, Landegent JE. Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity. Blood\u20081995; 85: 1188\u201394.","DOI":"10.1182\/blood.V85.5.1188.bloodjournal8551188"},{"key":"2022061700300162800_B47","unstructured":"Hapke DM, Stegmann AP, Mitchell BS. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res\u20081996; 56: 2343\u20137."},{"key":"2022061700300162800_B48","doi-asserted-by":"crossref","unstructured":"Jordheim LP, Galmarini CM, Dumontet C. Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells. Cancer Chemother Pharmacol\u20082006; 58: 547\u201354.","DOI":"10.1007\/s00280-006-0195-8"},{"key":"2022061700300162800_B49","doi-asserted-by":"crossref","unstructured":"Veuger MJ, Honders MW, Landegent JE, Willemze R, Barge RM. High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. Blood\u20082000; 96: 1517\u201324.","DOI":"10.1182\/blood.V96.4.1517.h8001517_1517_1524"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/7\/2349\/2592855\/2349.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/7\/2349\/2592855\/2349.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T01:33:21Z","timestamp":1655429601000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/7\/2349\/540749\/Two-Distinct-Molecular-Mechanisms-Underlying"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,1]]},"references-count":49,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2008,4,1]]},"published-print":{"date-parts":[[2008,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-5528","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22375317.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375320","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375320.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375317","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6497769.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6497769","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,1]]}}}